Sorna

Serna Bio is a biotechnology company focused on the discovery and development of small molecule drugs that target RNA. By leveraging its proprietary platform to map the "druggable transcriptome," the company aims to identify novel binding sites on RNA molecules that were previously considered undruggable. Serna Bio's approach combines high-throughput screening, computational biology, and RNA structural analysis to create a pipeline of first-in-class therapeutics for various indications, including oncology and rare diseases. The company is headquartered in London and is at the forefront of the emerging field of RNA-targeted small molecule discovery.